February 21, 2024
1 min watch
Save
VIDEO: Risankizumab ‘easy drug to discuss’ with psoriasis patients
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor risankizumab from the Maui Derm 2024 meeting.
Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed long-term studies into the use of risankizumab (Skyrizi, AbbVie) to treat palmoplantar psoriasis, as well as a long-term safety analysis.
“That safety looks very, very encouraging and makes it a really easy drug to discuss with our patients,” Chovatiya said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Chovatiya reports being an advisor, consultant, speaker and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi and UCB.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.